08:00 , Dec 3, 2015 |  BC Innovations  |  Targets & Mechanisms

The two faces of LTA4H

Although the enzyme LTA4H has long been considered a driver of inflammatory diseases, companies have yet to create an inhibitor that succeeds in the clinic beyond Phase II. That could be due to a secondary,...
07:00 , Jun 15, 2015 |  BioCentury  |  Finance

Domain finds unmet need in CF

Domain Associates has decided the best way to play the cystic fibrosis space is to find a molecule that can be combined with the ever-increasing number of cocktails emerging from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). To...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Financial News

Celtaxsys Inc. completes venture financing

Celtaxsys Inc., Atlanta, Ga.   Business: Pulmonary, Dermatology   Date completed: 2015-06-08   Type: Venture financing   Raised: $40 million   Investors: Domain Associates; Lumira Capital; RMI Partners; Masters Capital; Georgia Research Alliance Venture Fund   Note: Celtaxsys also received a...
02:10 , Jun 9, 2015 |  BC Extra  |  Financial News

Celtaxsys raises $40 million series D

Celtaxsys Inc. (Atlanta, Ga.) raised $40 million in a series D round led by Domain Associates, which invested through its Fund VIII. Also participating were Lumira Capital; RMI Partners; Masters Capital Management; and the Georgia...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

CTX-4430: Phase II started

Celtaxsys began a double-blind, placebo-controlled, Australian and New Zealand Phase II trial to evaluate 100 mg oral CTX-4430 once daily for 12 weeks in about 156 patients. Celtaxsys Inc., Atlanta, Ga.   Product: CTX-4430 (formerly...
07:00 , Apr 10, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Leukotriene A4 hydrolase (LTA4H) Structure-based design studies led to an LTA4H inhibitor that could be useful...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Clinical News

CTX-4430: Phase I started

Celtaxsys began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate 4 dose levels of oral CTX-4430 once daily for 15 days in about 36 patients. Celtaxsys acquired the compound from Estrellita Pharmaceuticals Inc....
08:00 , Jan 7, 2013 |  BC Week In Review  |  Clinical News

CTX-4430: Phase I started

Celtaxsys began the double-blind, placebo-controlled, Australian Phase I CTX-4430-HV-001 trial to evaluate single and multiple ascending-doses of once-daily, oral CTX-4430 in 96 healthy volunteers. Celtaxsys acquired the compound from Estrellita Pharmaceuticals Inc. (Belmont, Calif.)...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Company News

Celtaxsys Inc., Estrellita deal

Celtaxsys acquired exclusive, worldwide rights from Estrellita to CTX-4430. The company plans to begin a Phase I trial of the leukotriene A4 hydrolase (LTA4H) inhibitor to treat lung inflammation in cystic fibrosis (CF)...